Prostate cancer (hormone-refractory) - docetaxel
Docetaxel for the treatment of hormone refractory prostate cancer
Summary
Docetaxel is recommended as a possible treatment for men with hormone-refractory metastatic prostate cancer. It should be given only if the man is well enough to care for himself with occasional assistance. Treatment should be stopped at the end of a planned course of up to 10 cycles (or 'rounds' ...
Guidance documents
Implementing this guidance
Other information
We will consult on our review plans for this guidance in June 2009
About this guidance
Technology appraisals TA101
Issued: June 2006
How this guidance was produced
